Elevation Oncology Initiates Global Expansion of EO-3021 Phase 1 Trial with First Japanese Patient Dosing

Elevation Oncology, a company listed on the Nasdaq (ELEV), is advancing its Phase 1 clinical trial for EO-3021, a novel antibody drug conjugate (ADC), by expanding the study to include Japan. The drug targets Claudin 18.2, a protein often found in gastric and other solid tumors, and is designed to deliver a potent payload directly to cancer cells. The first patient in Japan has already been dosed as part of the trial, which is assessing EO-3021's safety, tolerability, and effectiveness against tumors. The company anticipates providing interim results in mid-2024, with further data to follow in the first half of 2025.

Dr. Valerie Malyvanh Jansen, Elevation Oncology's Chief Medical Officer, expressed enthusiasm for the expansion into Japan, noting the prevalence of gastric cancer patients who may benefit from the treatment. Dr. Kohei Shitara, the principal investigator of the trial and a leading expert in gastrointestinal oncology in Japan, also highlighted the potential of EO-3021 to offer new treatment options for patients with gastric cancer.

EO-3021 is an ADC that combines a monoclonal antibody with a cytotoxic drug, monomethyl auristatin E (MMAE), linked through a cleavable connector. The drug is currently in Phase 1 clinical trials (NCT05980416), an open-label, multi-center study that will also evaluate the correlation between Claudin 18.2 expression levels and treatment response. The trial is recruiting patients with specific types of advanced solid tumors across the U.S. and Japan.

Elevation Oncology holds exclusive global rights to develop and market EO-3021, except for Greater China. The company is dedicated to developing selective cancer therapies tailored to individual tumor profiles, with EO-3021 being a leading example. They are also exploring partnerships and business opportunities to broaden their oncology offerings.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!